Enriched clinical annotations |
For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched. |
Clinical annotation |
Category |
P-value |
Hits |
Hits(%) |
Module hits in category |
Arrays in annotation |
Arrays |
CNS tissue, cancer or cell line (Neuro tumors*) |
Neuro tumors* |
1.0e-24 |
53 |
18.1 |
292 |
85 |
1945 |
CNS cancer or cell line (Neuro tumors*) |
Neuro tumors* |
5.1e-23 |
50 |
17.1 |
292 |
81 |
1945 |
CNS tumor (Neuro tumors*) |
Neuro tumors* |
5.1e-23 |
50 |
17.1 |
292 |
81 |
1945 |
Cancer and cell line (Neuro tumors*) |
Neuro tumors* |
2.4e-21 |
50 |
17.1 |
292 |
86 |
1945 |
Cancer (Neuro tumors*) |
Neuro tumors* |
2.4e-21 |
50 |
17.1 |
292 |
86 |
1945 |
Hematologic cancer and cell line (Stimulated PBMC) |
Stimulated PBMC |
6.4e-21 |
23 |
92 |
25 |
30 |
182 |
Macrophages (Stimulated PBMC) |
Stimulated PBMC |
6.4e-21 |
23 |
92 |
25 |
30 |
182 |
Lung carcinoid (Lung cancer) |
Lung cancer |
1.8e-10 |
15 |
37.5 |
40 |
20 |
276 |
Cancer and cell line (Liver cancer) |
Liver cancer |
4.7e-10 |
38 |
100 |
38 |
126 |
207 |
Cell line (NCI60*) |
NCI60* |
2.0e-09 |
47 |
16.0 |
292 |
135 |
1945 |
Cancer and cell line (NCI60*) |
NCI60* |
4.7e-09 |
47 |
16.0 |
292 |
138 |
1945 |
Cell line (NCI60*) |
NCI60* |
1.2e-08 |
36 |
18.0 |
199 |
135 |
1945 |
Hematologic samples and cell lines (Various tumors) |
Various tumors |
2.3e-08 |
18 |
72 |
25 |
37 |
154 |
Hematologic samples (Various tumors) |
Various tumors |
2.3e-08 |
18 |
72 |
25 |
37 |
154 |
Cancer and cell line (NCI60*) |
NCI60* |
2.4e-08 |
36 |
18.0 |
199 |
138 |
1945 |
Hematologic cancer and cell line (NCI60) |
NCI60 |
8.2e-08 |
14 |
29.1 |
48 |
14 |
139 |
Hematologic samples and cell lines (NCI60) |
NCI60 |
8.2e-08 |
14 |
29.1 |
48 |
14 |
139 |
Leukemia cell line (NCI60) |
NCI60 |
8.2e-08 |
14 |
29.1 |
48 |
14 |
139 |
Cancer (Liver cancer) |
Liver cancer |
1.0e-06 |
34 |
89.4 |
38 |
115 |
207 |
Liver tissue, cancer or cell line (Liver cancer*) |
Liver cancer* |
5.6e-06 |
40 |
20.1 |
199 |
197 |
1945 |
Hematologic cancer and cell line (Various tumors) |
Various tumors |
1.1e-05 |
14 |
56 |
25 |
31 |
154 |
Hematologic cancer (Various tumors) |
Various tumors |
1.1e-05 |
14 |
56 |
25 |
31 |
154 |
Primary blood mononuclear cells (Various tumors) |
Various tumors |
1.1e-05 |
14 |
56 |
25 |
31 |
154 |
B. petrussis A2 stimulated immune cells (Stimulated PBMC) |
Stimulated PBMC |
1.7e-05 |
5 |
27.7 |
18 |
5 |
144 |
Lymphocytes (Various tumors) |
Various tumors |
2.0e-05 |
13 |
52 |
25 |
28 |
154 |
Monocytes (Various tumors) |
Various tumors |
2.0e-05 |
13 |
52 |
25 |
28 |
154 |
Fast doubling (20-40) cell lines (NCI60) |
NCI60 |
5.5e-05 |
43 |
93.4 |
46 |
90 |
122 |
Liver tissue (Liver cancer*) |
Liver cancer* |
6.3e-05 |
36 |
18.0 |
199 |
187 |
1945 |
Breast cancer cell line (Breast cancer) |
Breast cancer |
6.4e-05 |
9 |
40.9 |
22 |
17 |
152 |
Small cell lung cancer (Lung cancer) |
Lung cancer |
7.0e-05 |
7 |
17.5 |
40 |
10 |
276 |
Cell line (Breast cancer) |
Breast cancer |
7.5e-05 |
12 |
54.5 |
22 |
30 |
152 |
B cells (Various tumors) |
Various tumors |
9.3e-05 |
11 |
44 |
25 |
23 |
154 |
Atypical teratoid/rhabdoid tumour - CNS and other origin (Neuro tumors) |
Neuro tumors |
0.0001 |
6 |
54.5 |
11 |
10 |
90 |
Acute lymphocytic leukemia (Leukemia) |
Leukemia |
0.0001 |
20 |
100 |
20 |
99 |
149 |
Hematologic cancer and cell line (Stimulated immune*) |
Stimulated immune* |
0.0001 |
15 |
7.5 |
199 |
53 |
1945 |
Hematologic samples and cell lines (Stimulated immune*) |
Stimulated immune* |
0.0001 |
15 |
7.5 |
199 |
53 |
1945 |
Macrophages (Stimulated immune*) |
Stimulated immune* |
0.0001 |
15 |
7.5 |
199 |
53 |
1945 |
Monocytes (Stimulated immune*) |
Stimulated immune* |
0.0001 |
15 |
7.5 |
199 |
53 |
1945 |
Female hormonal cancer cell line (Breast cancer) |
Breast cancer |
0.0001 |
8 |
36.3 |
22 |
15 |
152 |
Metastasis (Liver cancer) |
Liver cancer |
0.0003 |
7 |
18.4 |
38 |
10 |
207 |
Mesenchemal cell line (Breast cancer) |
Breast cancer |
0.0003 |
4 |
18.1 |
22 |
4 |
152 |
Large cell lung cancer (Lung cancer) |
Lung cancer |
0.0004 |
3 |
21.4 |
14 |
4 |
276 |
Lymphoma (B lymphoma) |
B lymphoma |
0.0004 |
16 |
64 |
25 |
77 |
245 |